瘤微环境中的代谢-免疫联系:从机械学见解到治疗机会
Wenjie Zhu1,2, Yingchen Chu1, Peng Gao1,2
1Key Laboratory for Experimental Teratology of Ministry of Education, Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.
Chinese medical journal
|December 3, 2025
概括
癌细胞在瘤微环境 (TME) 中重新编程新陈代谢,创造了一个免疫抑制的利基. 针对这种代谢-免疫相互作用,提供了新的免疫疗法策略,以增强抗瘤反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢研究的研究.
背景情况:
- 瘤微环境 (TME) 是由癌细胞代谢重编程形成的,导致缺氧,酸化和营养物质耗尽.
- 癌细胞中的代谢变化会产生一种免疫抑制的利基,阻碍效应T细胞的功能,并促进抑制性免疫细胞.
研究的目的:
- 探索TME中的代谢-免疫相互作用.
- 通过准代谢途径,确定增强抗瘤免疫力的治疗机会.
主要方法:
- 对癌细胞中代谢重编程的分析.
- 对代谢物对免疫细胞功能影响的研究.
- 针对代谢-免疫轴的治疗策略的审查.
主要成果:
- 癌症代谢重编程限制了T细胞的营养,并产生免疫抑制代谢物 (乳酸盐,金氨酸,腺).
- 免疫细胞表现出不同的代谢适应性,效应性T细胞变得枯竭,抑制性细胞保持功能.
- 准癌症代谢或增强免疫细胞代谢适应性可以减轻TME免疫抑制.
结论:
- 调节代谢-免疫轴为癌症免疫治疗提供了一个有希望的策略.
- 将代谢调节剂与免疫疗法结合起来可以放大抗瘤反应.
- 需要进一步的研究,以克服临床翻译障碍,如目标特异性和毒性.
相关概念视频
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K


